Eli Lilly enters late-phase clinical trial for antibody treatment

Coronavirus Watch

(WEHT) Eli Lilly is making big progress in its antibody treatment clinical trial. The company is moving into a late-phase clinical trial of the antibody treatment for COVID-19.

The pharmaceutical giant said it’s recruiting 2,400 nursing home residents and staff for the trial, the population hardest-hit by the pandemic.

The hope is the therapy will offer protection and possibly ease symptoms for those who are infected.

The trial will determine if a single dose reduces the rate of infection over a month, as well as if it can reduce COVID-19 complications over two months.

As for a vaccine for COVID-19, the nation’s top disease doctors say they are still optimistic that a COVID-19 vaccine will happen by the end of this year or early 2021.

For the latest breaking news and stories from across the
Tri-State, follow Eyewitness News on Facebook and Twitter.

(This story was originally published on August 3, 2020)


Copyright 2021 Nexstar Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Trending Stories